Literature DB >> 21382171

Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis.

M Carrier1, M A Rodger, P S Wells, M Righini, G LE Gal.   

Abstract

BACKGROUND: Residual vein obstruction (RVO) detected on compression ultrasonography of the leg after a few months of anticoagulation therapy might be able to identify patients with deep vein thrombosis (DVT) at high risk of having a recurrent venous thromboembolism (VTE). AIM: To determine whether RVO is associated with an increased risk of recurrent events in patients with DVT. PATIENTS AND METHODS: A systematic literature search strategy was conducted using MEDLINE, EMBASE, and the Cochrane Register of Controlled Trials. We selected 14 articles (nine prospective cohort studies and five randomized controlled trials) that included patients with DVT who had an assessment for RVO with the use of compression ultrasonography. Two reviewers independently extracted data onto standardized forms.
RESULTS: Overall, the presence of RVO was not associated with an increased risk of recurrent VTE (odds ratio [OR] 1.24, 95% confidence interval [CI] 0.9-1.7) in patients with unprovoked DVT who stopped oral anticoagulation therapy at the time of RVO assessment. However, RVO was significantly associated with recurrent VTE in patients with any (unprovoked or provoked) DVT (OR 1.5, 95% CI 1.1-2.0).
CONCLUSIONS: RVO was associated with a modestly increased risk of recurrent VTE in patients with DVT (unprovoked and provoked). However, RVO did not seem to be a predictor of recurrent VTE in patients with unprovoked DVT following anticoagulation discontinuation. Further prospective studies are needed to assess the role of RVO in patients with unprovoked DVT.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Year:  2011        PMID: 21382171     DOI: 10.1111/j.1538-7836.2011.04254.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

Review 1.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Authors:  Fionnuala Ní Áinle; Barry Kevane
Journal:  Blood Adv       Date:  2020-11-10

4.  Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study.

Authors:  Bruna M Mazetto; Fernanda L A Orsi; Sandra A F Silveira; Luis F Bittar; Mariane M C Flores-Nascimento; Kiara C S Zapponi; Marina P Colella; Erich V de Paula; Joyce M Annichino-Bizzacchi
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

5.  Joint Guideline on Venous Thromboembolism - 2022.

Authors:  Ana Cristina Lopes Albricker; Cláudia Maria Vilas Freire; Simone Nascimento Dos Santos; Monica Luiza de Alcantara; Mohamed Hassan Saleh; Armando Luis Cantisano; José Aldo Ribeiro Teodoro; Carmen Lucia Lascasas Porto; Salomon Israel do Amaral; Orlando Carlos Gloria Veloso; Ana Cláudia Gomes Pereira Petisco; Fanilda Souto Barros; Márcio Vinícius Lins de Barros; Adriano José de Souza; Marcone Lima Sobreira; Robson Barbosa de Miranda; Domingos de Moraes; Carlos Gustavo Yuji Verrastro; Alexandre Dias Mançano; Ronaldo de Souza Leão Lima; Valdair Francisco Muglia; Cristina Sebastião Matushita; Rafael Willain Lopes; Artur Martins Novaes Coutinho; Diego Bromfman Pianta; Alair Augusto Sarmet Moreira Damas Dos Santos; Bruno de Lima Naves; Marcelo Luiz Campos Vieira; Carlos Eduardo Rochitte
Journal:  Arq Bras Cardiol       Date:  2022-04       Impact factor: 2.000

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism.

Authors:  Wendy Lim; Grégoire Le Gal; Shannon M Bates; Marc Righini; Linda B Haramati; Eddy Lang; Jeffrey A Kline; Sonja Chasteen; Marcia Snyder; Payal Patel; Meha Bhatt; Parth Patel; Cody Braun; Housne Begum; Wojtek Wiercioch; Holger J Schünemann; Reem A Mustafa
Journal:  Blood Adv       Date:  2018-11-27

7.  Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

Authors:  F Dentali; S Barco; S Pegoraro; M N D Di Minno; D Mastroiacovo; F Pomero; C Lodigiani; F Bagna; M Sartori; G Barillari; N Mumoli; M Napolitano; S M Passamonti; R Benedetti; W Ageno; M Di Nisio
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 8.  Assessing the risk of recurrent venous thromboembolism--a practical approach.

Authors:  Jennifer Fahrni; Marc Husmann; Silvia B Gretener; Hong H Keo
Journal:  Vasc Health Risk Manag       Date:  2015-08-17

9.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13

Review 10.  Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.

Authors:  Paul E Marik; Rodrigo Cavallazzi
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.